Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Epilepsy

Erata is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy. It is also indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy, in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy, and in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

⚠️ Always consult a registered physician before taking any medicine.

Pregnancy & Breastfeeding

Levetiracetam isn't generally recommended during pregnancy, and women of childbearing age who aren't using contraception should avoid it unless there's a clear clinical need. The drug does pass into human breast milk, so breastfeeding isn't recommended either. That said, if a mother needs to continue levetiracetam while breastfeeding, the decision should weigh the treatment's benefits and risks against the value of breastfeeding itself. Animal studies haven't shown any effect on fertility, but since no clinical data exist in humans, the actual risk to people remains unknown.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Dosage Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily, increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be raised further by 250 mg twice daily every two weeks according to clinical response, up to a maximum of 1500 mg twice daily. Adults (18 years and above) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily, and this dose can be started from the first day of treatment. Depending on clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes should be made in steps of 500 mg twice daily, increasing or decreasing every two to four weeks. Pediatric population: The tablet formulation is not suitable for infants and children under 6 years of age; the oral solution is the preferred formulation for this group. The available tablet strengths are also not appropriate for starting treatment in children weighing less than 25 kg, for patients who cannot swallow tablets, or for giving doses below 250 mg. In all these situations, the oral solution should be used instead. Monotherapy: The safety and efficacy of levetiracetam as monotherapy in children and adolescents below 16 years have not been established. Add on therapy: The oral solution is the preferred formulation for infants and children under 6 years of age. For children aged 6 years and above, the oral solution should be used for doses under 250 mg, for doses that are not exact multiples of 250 mg and so cannot be given accurately with whole tablets, and for patients unable to swallow tablets. The lowest effective dose should always be used. A child or adolescent weighing 25 kg should start at 250 mg twice daily, with a maximum dose of 750 mg twice daily. For children weighing 50 kg or more, dosing follows the same schedule as in adults. Add on therapy for infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in this age group.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.